AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|
23.6 C
New York
Tuesday, July 21, 2026

Tag: mice

newssourceFORcompanyinformationcontent1releasesmarket

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

Chalk River Laboratories Becomes First GLP-Certified Laboratory in Canada to Offer Pre-Clinical Radiopharmaceutical Studies

Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory 
Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

USD 235 Million Birkin International Hotel Opens in Melaka, Redefining Sustainable Luxury for the Modern Traveller

MALACCA, Malaysia, July 11, 2025 /PRNewswire/ -- Birkin International Hotel, a landmark in sustainable luxury, had officially opened its doors on July 9 in...

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation...

Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital and others Dr. Emilio Emini, former SVP of...

Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections

INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Mach Conferences & Events Limited Secures Seven High-Value Orders Across BFSI, Cement, and Auto Industries in the Last 15 Days, Reaffirming Its Leadership in...

NEW DELHI, June 30, 2025 /PRNewswire/ -- Mach Conferences & Events Limited, a trailblazer in India's MICE (Meetings, Incentives, Conferences, and Exhibitions) industry, proudly...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMice

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers